Skip to main content

Table 1 Studies without comparative purpose

From: Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy

Author [ref.] Pts (no.) Cancer (type) Chemotherapy (emetogenicity) Antiemetics HRQL assessment (times) Selection of pts
Lindley [8] 122 various various various FLIC and FLIE (before and after 3 days) 162 pts eligible, 140 agreed to participate, 122 evaluated HRQL
Berry [10] 109 various various OND use compassionate FLIE (n.s.) 350 pts, 190 received similar CT, 109 evaluated HRQL
O'Brien [11] 92 various Moderately and highly DEX + MTC or PCP ± other FLIE (before and after 2 and 5 days) 128 pts eligible, 112 agreed to participate, 107 evaluated HRQL (15 pts excluded for multiple days CT)
Osoba [12] 802 various Moderately and highly 5-HT3 ± DEX EORTC QLQ-C30 (before and after 7 days)  
Osoba [13] 802 various Moderately and highly 5-HT3 ± DEX EORTC QLQ-C30 (before and after 7 days) Possible selection bias at HRQL evaluated before 2nd cycle CT (70% of pts)
Rusthoven [16] 119 various Moderately Standard for Centers EORTC QLQ-C30 (before and after 2 and 6 days) 124 pts eligible, 119 evaluated HRQL
  1. CT: chemotherapy, DEX: dexamethasone, HRQL: Health-related quality of life, OND: ondansetron, PCP: prochlorperazine, 5-HT3: 5-HT3 antagonist, n.s.: not specified.